Mood Stabilizers, Anticonvulsants, and Anti-agitants

  • William J. NewmanEmail author


This chapter addresses the use of mood stabilizers, including various anticonvulsants, for both FDA-approved and off-label uses in treating psychiatric disorders. Additionally, this chapter provides a focused overview of the management of adults with aggressive behaviors related to major psychiatric disorders, with an emphasis on conditions most likely to be encountered by neurologists. There are no FDA-approved pharmacological treatments of aggression, regardless of diagnosis or the origin of the behaviors. The treatments used to target aggression (beyond primary treatment of psychiatric disorders) are therefore off-label interventions and should be carefully considered after reviewing the available evidence. This chapter presents some of the relevant evidence supporting off-label pharmacological treatments targeting aggression related to specific diagnoses. Other sources provide more detailed overviews of the assessment and management of aggression.


Mood stabilizers Lithium Valproate Anticonvulsants Aggression Bipolar disorder Neurocognitive disorders Anti-agitant drugs 


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  2. 2.
    American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder [Electronic Version]. 2002 Retrieved July 21, 2015 from
  3. 3.
    Quanbeck CD, Stone DC, Scott CL, et al. Clinical and legal correlates of inmates with bipolar disorder at time of criminal arrest. J Clin Psychiatry. 2004;65(2):198–203.CrossRefPubMedGoogle Scholar
  4. 4.
    Asnis GM, Kaplan ML, Hundorfean G, et al. Violence and homicidal behaviors in psychiatric disorders. Psychiatr Clin North Am. 1997;20(2):405–25.CrossRefPubMedGoogle Scholar
  5. 5.
    McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry. 1999;60:S3–80.CrossRefGoogle Scholar
  6. 6.
    Wang Y, Xia J, Helfer B, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016;11:CD004028.PubMedGoogle Scholar
  7. 7.
    Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry. 1998;31:122–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Bender S, Linka T, Wolstein J, Gehendges S, Paulus HJ, Schall U, Gastpar M. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol. 2004;7(1):59–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand. 1989;80:250–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Pavlovic ZM. Augmentation of clozapine’s antiaggressive properties with lamotrigine in a patient with chronic disorganized schizophrenia. J Clin Psychopharmacol. 2008;28(1):119–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28(6):1186–97.CrossRefPubMedGoogle Scholar
  12. 12.
    Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133:1409–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Newman WJ, McDermott BE. Beta blockers for violence prophylaxis – case reports. J Clin Psychopharmacol. 2011;31(6):785–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62(3):199–203.CrossRefPubMedGoogle Scholar
  15. 15.
    Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, Fartacek R, Lahmann C, Buschmann W, Tritt K, Bachler E, Mitterlehner F, Pedrosa Gil F, Leiberich P, Rother WK, Egger C. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26(1):61–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1515–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;6:CD005653.Google Scholar
  18. 18.
    Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, Nickel MK. Lamotrigine treatment of aggression in female borderline patients: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;9(3):287–91.CrossRefGoogle Scholar
  19. 19.
    Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24(5):270–5.PubMedGoogle Scholar
  20. 20.
    Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986;47:423–6.PubMedGoogle Scholar
  21. 21.
    Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propranolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis. 1986;174:290–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Greendyke RM, Berkner JP, Webster JC, Gulya A. Treatment of behavioral problems with pindolol. Psychosomatics. 1989;30(2):161–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H, Hirschmann H, Ritsner M. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol. 2001;16(2):111–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Geracioti TD. Valproic acid treatment of episodic explosiveness related to brain injury. J Clin Psychiatry. 1994;55:416–7.PubMedGoogle Scholar
  25. 25.
    Horne M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes. J Clin Psychiatry. 1995;56:430–1.PubMedGoogle Scholar
  26. 26.
    Wroblewski BA, Joseph AB, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviors in patients with acquired brain injury. Brain Inj. 1997;11:37–47.CrossRefPubMedGoogle Scholar
  27. 27.
    Azouvi P, Jokic C, Attal N, Denys P, Markabi S, Bussel B. Carbamazepine in agitation and aggressive behavior following severe closed-head injury: results of an open trial. Brain Inj. 1999;13:797–804.CrossRefPubMedGoogle Scholar
  28. 28.
    Haas JF, Cope DN. Neuropharmacologic management of behavior sequelae in head injury: a case report. Arch Phys Med Rehabil. 1985;66:472–4.PubMedGoogle Scholar
  29. 29.
    Hornstein A, Seliger G. Cognitive side effects of lithium in closed head injury. J Neuropsychiatr Clin Neurosci. 1989;1:446–7.CrossRefGoogle Scholar
  30. 30.
    Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj. 2004;18:1–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;2:CD005594.Google Scholar
  32. 32.
    Wilson MP, Pepper D, Currier GW, Holloam GH, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. West J Emerg Med. 2012;13:26–34.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pun BT, Ely EW. The importance of diagnosing and managing ICU delirium. Chest. 2007;132:624–36.CrossRefPubMedGoogle Scholar
  34. 34.
    Craft M, Ismail IA, Krishnamurti D, Mathews J, Regan A, Seth RV, North PM. Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry. 1987;150:685–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Spreat S, Behar D, Reneski B, Miazzo P. Lithium carbonate for aggression in mentally retarded persons. Compr Psychiatry. 1989;30:505–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Tyrer SP, Walsh A, Edwards DE, Berney TP, Stephens DA. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Prog Neuro-Psychopharmacol Biol Psychiatry. 1984;8:751–5.CrossRefGoogle Scholar
  37. 37.
    Mattes JA. Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Ment Dis. 1992;180:601–2.CrossRefPubMedGoogle Scholar
  38. 38.
    Amore M, Bertelli M, Villani D, Tamborini S, Rossi M. Olanzapine vs. risperidone in treating aggressive behaviors in adults with intellectual disability: a single blind study. J Intellect Disabil Res. 2011;55(2):210–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Hassler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: a review of the current literature. Dev Disabil Res Rev. 2010;16(3):265–72.CrossRefPubMedGoogle Scholar
  40. 40.
    Ruedrich SL, Grush L, Wilson J. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard. 1990;95(1):110–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral NeuroscienceSaint Louis University School of MedicineSt. LouisUSA

Personalised recommendations